Tropidil1%

Tropidil 1% ophthalmic solution is used to produce mydriasis (pupil dilation) and cycloplegia (temporary paralysis of the eye's focusing muscle) for diagnostic eye examinations and procedures, including:

• Routine dilated fundus examination, to allow the eye doctor to view the retina and back of the eye
• Cycloplegic refraction - determining a patient's true glasses prescription by temporarily relaxing the eye's accommodation (focusing) reflex, particularly important in children where accommodation can mask the true refractive error
• Pupil dilation before certain laser or surgical eye procedures

Tropidil 1% is for diagnostic use only, administered by or under the direction of an eye care professional; it is not intended for ongoing therapeutic use.

Contains Tropidil 1% as the active ingredient, available as an ophthalmic solution in two strengths, 0.5% and 1%. The two strengths have different clinical uses; confirm which strength is being used, since the 1% solution produces more complete cycloplegia (for refraction) while the 0.5% solution is often used mainly for pupil dilation for fundus examination.

Tropidil 1% is a short-acting anticholinergic eye drop used by eye doctors to dilate the pupil and temporarily relax the eye's focusing muscle for examination or diagnostic testing. It shares the same general mechanism as atropine but has a much shorter duration of action, with the eye typically returning to normal within about 4-8 hours (occasionally up to 24 hours), making it convenient for same-day office use. It is used only for diagnostic purposes, under the direction of an eye care professional.

Therapeutic Class: Ophthalmic Mydriatic / Cycloplegic Agent

Tropidil 1% has greater mydriatic (pupil-dilating) than cycloplegic (focus-paralysing) potency at typical concentrations, which is clinically important, since visible pupil dilation does not necessarily indicate that cycloplegia is complete - relevant when accurate cycloplegic refraction is needed. Maximum pupil dilation typically occurs within about 20-40 minutes of instillation. Unlike atropine, Tropidil 1% does not bind as firmly to eye tissue, giving it a much shorter duration of action. Patients with heavily pigmented (dark brown) irides may require a higher concentration or additional doses to achieve the same effect as those with lighter irides.

• Administered by, or under the direct supervision of, an eye care professional
• Instilled as drops into the conjunctival sac
• To minimize systemic absorption, apply gentle pressure to the inner corner of the eye (over the tear duct) for 1-2 minutes after instillation
• Contact lenses should be removed before administration
• Wash hands after administration to avoid accidental transfer to the eyes or mouth

Systemic absorption from topical ophthalmic use is generally limited but can be clinically relevant, particularly in infants, given Tropidil 1%'s anticholinergic activity. The following should be considered:

• Other anticholinergic medicines (systemic or ophthalmic): may have additive antimuscarinic effects when combined with Tropidil 1%.
• Other mydriatic eye drops used in combination (such as phenylephrine or cyclopentolate, sometimes used together for enhanced dilation): can increase both the dilating effect and the risk of systemic anticholinergic or sympathomimetic side effects, particularly in infants; combination regimens should follow specific institutional protocols.

Common side effects

• Temporary blurred vision and light sensitivity (photophobia) while the pupil is dilated
• Eye stinging on instillation
• Increased intraocular pressure (transient)

Less common side effects

• Dizziness, headache
• Dry mouth

Serious side effects (more relevant in infants and young children - seek medical attention)

• Central nervous system disturbances: psychotic reactions, behavioural disturbances, and, rarely, vasomotor or cardiorespiratory collapse have been reported with anticholinergic eye drops in children
• In newborns, particularly preterm infants, gastrointestinal effects have been reported, including rare cases of necrotising enterocolitis associated with combination mydriatic regimens used for retinopathy of prematurity screening
• Acute angle-closure glaucoma in susceptible individuals: severe eye pain, redness, and vision loss

Pregnancy

Tropidil 1% is used for diagnostic eye examinations during pregnancy when clinically necessary, given its short duration of action and generally low systemic absorption with proper administration technique (including tear-duct pressure); discuss any concerns with your eye doctor.

Breastfeeding

Systemic absorption from topical ophthalmic use is generally low; Tropidil 1% is commonly used for diagnostic purposes in breastfeeding women, though specific data are limited.

• Pediatric CNS safety: Tropidil 1% may rarely cause central nervous system disturbances, which can be dangerous in pediatric patients; use the lowest effective concentration and dose in children, and monitor accordingly.
• Angle-closure glaucoma risk: can precipitate acute angle-closure glaucoma in patients with narrow anterior chamber angles; the eye doctor typically assesses this risk before dilation.
• Visual disturbance after use: patients should not drive or engage in hazardous activities while their pupils remain dilated and vision is blurred, until the effect has worn off.
• Inflamed eyes absorb topical medicines more readily, increasing systemic absorption; use with additional caution in this setting.
• Heavily pigmented irides may require a higher concentration or additional doses for adequate effect.

Systemic overdose or excessive absorption of Tropidil 1% can produce anticholinergic toxicity, with symptoms such as flushed, dry skin, dry mouth, rapid heartbeat, fever, reduced sweating, and, particularly in children, central nervous system effects including agitation, confusion, or hallucinations. Suspected significant systemic overdose requires prompt medical evaluation; treatment is generally supportive, provided in a medical facility.

Store at 8-27°C (46-80°F); do not refrigerate. Protect from light and keep the container tightly closed. Do not use if the protective seal is not intact.

• Infants and neonates, especially preterm infants: More susceptible to systemic anticholinergic effects and, with combination mydriatic regimens, gastrointestinal complications; the lowest effective concentration and number of doses should be used, with close monitoring, particularly during retinopathy of prematurity screening.
• Children generally: May rarely experience CNS disturbances; use with caution and appropriate monitoring.
• Elderly: Increased risk of precipitating angle-closure glaucoma if undiagnosed narrow angles are present; the eye doctor typically assesses anterior chamber depth before dilation in this population.

Tropidil 1% is used only for the duration of a single diagnostic examination or procedure, not for ongoing therapeutic use. Its effects (dilation and cycloplegia) typically reverse spontaneously within 4-8 hours, though complete recovery may occasionally take up to 24 hours.

Drug Class: Anticholinergic (antimuscarinic) mydriatic-cycloplegic

Tropidil 1% blocks the action of acetylcholine at muscarinic receptors in the eye, relaxing the sphincter muscle of the iris (which normally constricts the pupil) and the ciliary muscle (which controls focusing). With the constricting muscle relaxed and unopposed by the eye's separate dilating muscle, the pupil widens (mydriasis); the ciliary muscle relaxation temporarily prevents the eye from actively focusing (cycloplegia).

Tropidil 1% is commonly used in infants and children for pupil dilation and cycloplegic refraction, with the specific concentration, number of drops, and timing following age-specific protocols (for example, some guidelines recommend two drops of 1% Tropidil 1% 5 minutes apart for infants under 6 months, or combination regimens with cyclopentolate for older children). Because pediatric patients, especially neonates, are more susceptible to systemic anticholinergic effects, the lowest effective dose is used, with monitoring for CNS or gastrointestinal disturbances.